99 related articles for article (PubMed ID: 2080047)
1. 5,10-Dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF): a potent inhibitor of purine biosynthesis.
Nutr Rev; 1990 Nov; 48(11):421-3. PubMed ID: 2080047
[No Abstract] [Full Text] [Related]
2. The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis.
Moran RG; Baldwin SW; Taylor EC; Shih C
J Biol Chem; 1989 Dec; 264(35):21047-51. PubMed ID: 2592365
[TBL] [Abstract][Full Text] [Related]
3. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.
Beardsley GP; Moroson BA; Taylor EC; Moran RG
J Biol Chem; 1989 Jan; 264(1):328-33. PubMed ID: 2909524
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.
Taylor EC; Hamby JM; Shih C; Grindey GB; Rinzel SM; Beardsley GP; Moran RG
J Med Chem; 1989 Jul; 32(7):1517-22. PubMed ID: 2738886
[TBL] [Abstract][Full Text] [Related]
5. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase.
Baldwin SW; Tse A; Gossett LS; Taylor EC; Rosowsky A; Shih C; Moran RG
Biochemistry; 1991 Feb; 30(7):1997-2006. PubMed ID: 1993209
[TBL] [Abstract][Full Text] [Related]
6. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function.
Bronder JL; Moran RG
Cancer Res; 2002 Sep; 62(18):5236-41. PubMed ID: 12234990
[TBL] [Abstract][Full Text] [Related]
7. (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells.
Pizzorno G; Moroson BA; Cashmore AR; Beardsley GP
Cancer Res; 1991 May; 51(9):2291-5. PubMed ID: 1707749
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological activity of 7-oxo substituted analogues of 5-deaza-5,6,7,8-tetrahydrofolic acid (5-DATHF) and 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF).
Borrell JI; Teixidó J; Matallana JL; Martínez-Teipel B; Colominas C; Costa M; Balcells M; Schuler E; Castillo MJ
J Med Chem; 2001 Jul; 44(14):2366-9. PubMed ID: 11428931
[TBL] [Abstract][Full Text] [Related]
9. Synergy between 5,10-dideaza-5,6,7,8-tetrahydrofolic acid and methotrexate in mice bearing L1210 tumors.
Ferguson K; Boschelli D; Hoffman P; Oronsky A; Whiteley J; Webber S; Galivan J; Freishiem J; Hynes J; Kerwar SS
Cancer Chemother Pharmacol; 1989; 25(3):173-6. PubMed ID: 2598407
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of 2-desamino-2-methyl-10-propagyl-5,8-dideazafolic acid cytotoxicity by 5,10-dideazatetrahydrofolate in L1210 cells with decrease in DNA fragmentation and deoxyadenosine triphosphate pools.
Kwok JB; Tattersall MH
Biochem Pharmacol; 1991 Jul; 42(3):507-13. PubMed ID: 1859463
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological properties of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid.
Boschelli DH; Webber S; Whiteley JM; Oronsky AL; Kerwar SS
Arch Biochem Biophys; 1988 Aug; 265(1):43-9. PubMed ID: 3166364
[TBL] [Abstract][Full Text] [Related]
12. Thienyl and thiazolyl acyclic analogues of 5-deazatetrahydrofolic acid.
Hodson SJ; Bigham EC; Duch DS; Smith GK; Ferone R
J Med Chem; 1994 Jun; 37(13):2112-5. PubMed ID: 8027993
[TBL] [Abstract][Full Text] [Related]
13. Induction of HL-60 leukemia cell differentiation by the novel antifolate 5,10-dideazatetrahydrofolic acid.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Res; 1989 Sep; 49(17):4824-8. PubMed ID: 2758415
[TBL] [Abstract][Full Text] [Related]
14. A simplified and efficient synthesis of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF).
Taylor EC; Chaudhari R; Lee K
Invest New Drugs; 1996; 14(3):281-5. PubMed ID: 8958183
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activity of 4-amino-7-oxo-substituted analogues of 5-deaza-5,6,7,8-tetrahydrofolic acid and 5,10-dideaza-5, 6,7,8-tetrahydrofolic acid.
Borrell JI; Teixidó J; Martínez-Teipel B; Matallana JL; Copete MT; Llimargas A; García E
J Med Chem; 1998 Aug; 41(18):3539-45. PubMed ID: 9719607
[TBL] [Abstract][Full Text] [Related]
16. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
Zhao R; Gao F; Babani S; Goldman ID
Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
Erba E; Sen S; Sessa C; Vikhanskaya FL; D'Incalci M
Br J Cancer; 1994 Feb; 69(2):205-11. PubMed ID: 8297715
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of alpha- and gamma-carboxamide derivatives of 10-CF3CO-DDACTHF.
Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
Bioorg Med Chem; 2005 May; 13(10):3587-92. PubMed ID: 15848771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
